Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates
04 nov. 2019 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019
28 oct. 2019 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019
29 mai 2019 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
06 mai 2019 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
29 avr. 2019 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
28 nov. 2018 08h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
09 avr. 2018 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting
05 déc. 2016 08h00 HE
|
Minerva Neurosciences, Inc.
Oral presentation highlights specific improvements in negative symptoms and cognition observed in schizophrenic patients treated with MIN-101 in Phase IIB trial Data also presented from Phase IIA...
Minerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting
13 oct. 2016 08h30 HE
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs
26 sept. 2016 08h30 HE
|
Minerva Neurosciences, Inc.
Last patient completes extension phase of Phase IIb trial with MIN-101 Company receives FDA acceptance of Investigational New Drug Application for MIN-117 WALTHAM, Mass., Sept. 26, 2016 (GLOBE...